Genomic Profiling in Luminal Breast Cancer

The developments in gene expression analysis have made it possible
tosub-classify hormone receptor-positive (luminal) breast cancer
indifferent prognostic subgroups. This sub-classification is
currentlyused in clinical routine as prognostic signature (e. g.
21-gene OnoctypeDX (R), 70-gene Mammaprint (R)). As yet, the
optimal method forsub-classification has not been defined.
Moreover, there is no evidencefrom prospective trials. This review
explores widely used genomicsignatures in luminal breast cancer,
making a critical appraisal ofevidence from
retrospective/prospective trials. It is based onsystematic
literature search performed using Medline (accessed September2013)
and abstracts presented at the Annual Meeting of American Societyof
Clinical Oncology and San Antonio Breast Cancer Symposium.